Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
14th December 2020 | David A Gonyer | 23,954 | Open or private sale | $2.94 | $70,424.76 |
11th December 2020 | David A Gonyer | 48,046 | Open or private sale | $2.90 | $139,333.40 |
11th December 2020 | Matthew J D'Onofrio | 40,357 | Open or private sale | $2.91 | $117,438.87 |
10th December 2020 | Matthew J D'Onofrio | 5,643 | Open or private sale | $2.95 | $16,646.85 |
1st September 2020 | David A Gonyer | 20,238 | Other acquisition or disposition | $1.05 | $21,249.90 |
1st September 2020 | Matthew J D'Onofrio | 20,238 | Other acquisition or disposition | $1.05 | $21,249.90 |
1st September 2020 | Marilyn R. Carlson | 20,238 | Other acquisition or disposition | $1.05 | $21,249.90 |
2nd March 2020 | Matthew J D'Onofrio | 25,000 | Grant/award etc. | $0.85 | $21,250.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Evoke Pharma, Inc. develops Gimoti, with promotility and anti-emetic effects. Gimoti is for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.
14th January 2021
10th November 2020
6th November 2020
6th November 2020
6th November 2020